


下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESC66Cat. No.: HY-19832CAS No.: 871361-88-5分式: CHNO分量: 276.33作靶點: Akt; Apoptosis作通路: PI3K/Akt/mTOR; Apoptosis儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 34 mg/mL (123.04 mM)* means solub
2、le, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.6189 mL 18.0943 mL 36.1886 mL5 mM 0.7238 mL 3.6189 mL 7.2377 mL10 mM 0.3619 mL 1.8094 mL 3.6189 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 SC66種 Akt 抑制劑,降低細胞活,這種作存在劑量和時間依賴性,且抑制肝癌 (HCC) 細胞的集落形成和誘
3、導凋亡。IC50 & Target Akt體外研究SC66 inhibits cell viability and colony forming capacity of HCC cells with IC50s of 0.77,0.47,0.92,0.751/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEand 2.85 g/mL at 72 hours for HepG2, Hep3B, PLC/PRF/5,HA22T/VGH and Huh7 cells. HepG2,HA22T/VGH and PLC/PRF/5 cells have si
4、milar IC50s of approximately 0.85 and 0.75 g/mL at 48 and 72hours, respectively. To determine whether the decrease in cell viability is related to apoptosis induction,TUNEL assays are performed in Hep3B and Huh7 cells treated with 1, 2 and 4 g/mL of SC66 for 24 hours.In Hep3B cells the number of TUN
5、EL-positive cells increased with increasing concentrations of SC66,whereas in Huh7 cells very few light brown-colored cells are observed only after treatment with 4 g/mLSC66 1.體內(nèi)研究 To demonstrate the effectiveness in vivo of SC66 on HCC, a mouse xenograft tumor model of Hep3B cells isused. When tumo
6、rs became palpable, at a size of about 150 mm3, mice are randomized into three groups of6 animals each. The treated group receive SC66 at 15 and 25 mg/kg twice a week via i.p. injection, while theuntreated group receive the vehicle alone. Treatment with 25 mg/Kg SC66 significantly reduces tumorvolum
7、e to 37% on day 17 when compared with tumors of the untreated group 1.PROTOCOLCell Assay 1 Cells (5 103/well) are distributed into each well of 96-well microtiter plates and then incubated overnight. Attime 0, the medium is replaced with fresh complete medium and different doses of SC66 are added. C
8、ells arecultured for 24, 48 and 72 hours. At the end of treatment, MTS assays are performed using the CellTiterAqueous OneSolution kit. Cell viability is expressed as a percentage of the absorbance measured in thecontrol cells. Values are expressed as meansSD of three separate experiments, each perf
9、ormed in triplicate1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 Male nude athymic mice (Fox1 nu/nu) aged 4 weeks are used. Suspensions of 1107 Hep3B cells in 0.2 mLof PBS are inoculated into the right flank of the anim
10、al. When tumors became palpable (around 150 mm3),the mice are randomly divided into three groups of 6 animals each, with the various tumor volumes equallydistributed among the three groups. Two groups of mice are treated twice a week with 15 and 25 mg/kgSC66 suspended in DMSO, further diluted in a s
11、olution of 25% ethanol and administered via i.p. injection.The control group receive the vehicle alone. Tumor volumes are determined twice a week using calipers.Primary tumor volumes are calculated.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Cusimano A, et al. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget. 2015Jan 30;6(3):1707-22.McePdfHeightCaution: Product
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 中國花卉藝術(shù)行業(yè)市場發(fā)展分析及發(fā)展趨勢與投資機會研究報告2025-2028版
- 中國自動鎖鎖芯行業(yè)市場發(fā)展前景及發(fā)展趨勢與投資戰(zhàn)略研究報告2025-2028版
- 創(chuàng)作中旋律與和聲的統(tǒng)一試題及答案
- 2025年注冊土木工程師考前評估試題及答案
- ③寒假提升-專題05 完形填空(學生版)2025年高一英語寒假銜接講練 (人教版)
- 2024年東菀市社衛(wèi)中心招聘真題
- 2025年土木工程師注冊考試高分技巧試題及答案
- 2025年新能源汽車技術(shù)產(chǎn)業(yè)化分析試題及答案
- 商務(wù)英語視覺傳達試題及答案
- 2025年大學化學考試綠色化學反應(yīng)試題及答案
- 新高考背景下高考數(shù)學重點板塊分析與教學建議課件
- 物業(yè)五級三類服務(wù)統(tǒng)一標準
- 肥胖患者麻醉管理專家共識
- 全廠接地裝置安裝施工方案
- 山東省青島市膠州市2023-2024學年高二下學期期末學業(yè)水平檢測數(shù)學試題
- 成都市2022級(2025屆)高中畢業(yè)班摸底測試(零診) 語文試卷(含答案)
- 作家太宰治課件
- 中國系統(tǒng)性紅斑狼瘡診療指南
- 部編人教版高中英語選擇性必修二教學設(shè)計全套
- 浙江省杭州市余杭區(qū)2023-2024學年六年級下學期期中數(shù)學試卷
- 建筑邊坡工程監(jiān)測技術(shù)標準
評論
0/150
提交評論